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Computational vaccine design, also known as computational vaccinology, encompasses epitope mapping, antigen
selection and immunogen design using computational tools. The iVAX toolkit is an integrated set of tools that has been
in development since 1998 by De Groot and Martin. It comprises a suite of immunoinformatics algorithms for triaging
candidate antigens, selecting immunogenic and conserved T cell epitopes, eliminating regulatory T cell epitopes, and
optimizing antigens for immunogenicity and protection against disease. iVAX has been applied to vaccine
development programs for emerging infectious diseases, cancer antigens and biodefense targets. Several iVAX vaccine
design projects have had success in pre-clinical studies in animal models and are progressing toward clinical studies.
The toolkit now incorporates a range of immunoinformatics tools for infectious disease and cancer immunotherapy
vaccine design. This article will provide a guide to the iVAX approach to computational vaccinology.
Introduction
After two decades of testing and validation, methods for
selecting and optimizing antigens using computational vacci-
nology tools have been integrated into the vaccine develop-
ment process in numerous commercial and academic vaccine
discovery programs. Even more recently, vaccinologists have
recognized the role that in silico immunogenicity assessments
can play in terms of understanding the efficacy of licensed
vaccines. As much for immunopathogenesis as for antigen
selection or prediction of vaccine efficacy, immunoinfor-
matics tools have proven to be essential components of the
complete vaccine toolkit. The number of tools available has
expanded dramatically over the last few years, as well as the
number of published studies citing “immunoinformatics” or
“computational vaccinology” (Fig. 1). Individual computa-
tional vaccinology tools, primarily for epitope prediction, are
available from a range of sources, such as Jenner-predict1
and VaxiJen2 and IEDB.3
While a selection of computational vaccinology tools are avail-
able, most of these tools are ‘stand-alone’ algorithms that have
not been integrated into a single, continuous workflow. Begin-
ning in 2002, Martin and De Groot at EpiVax have developed
an integrated approach to computational vaccine design that was
first described in 2003 at a seminal meeting organized by the
Novartis Foundation.4 This set of tools has been further devel-
oped and expanded into a single integrated online website, the
iVAX toolkit. The toolkit uniquely offers immunoinformatics-
driven antigen selection and epitope-based vaccine design as well
as the potential for vaccine enhancement using epitope-based
immune modulation and removal of Treg epitopes that are dis-
covered using the toolkit. A high-level summary of recent work
performed with the iVAX toolkit is provided here, including brief
examples of vaccine projects that illustrate the individual tools.
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Computational vaccinology
Genome- and ‘immunome’-mining tools have played a major
role in the design and development of subunit and epitope-based
vaccines for infectious diseases in the last decade. The process
was at first called “vaccinomics” by Brusic and Petrovsky in
2002.5 Alternative terms include “reverse vaccinology,” a term
coined by Rappuoli in 20036 and “immunome-derived or
genome-derived vaccine design” by Pederson;7 De Groot and
Martin;4 and Doytchinova, Taylor, and Flower (Fig. 2).8 This
method uses computational algorithms to identify a minimal set
of immunogens, which may be whole proteins or individual epit-
opes, which will induce a competent immune response to a
pathogen or neoplasm. Enhancement of existing antigens by inte-
grating conserved and immunogenic epitopes, and administra-
tion of these immunogens in the right delivery vehicle and with
the correct adjuvant has been shown to drive immune responses
against infection the pathogen. In short, the computational
approach to developing vaccines is based on the concept that
selection and design of the epitope or antigen ‘payload’ is criti-
cally important for vaccine development.
Immunoinformatics, as applied to computational vaccinology,
allows selection of the payload with significant advantages over
conventional vaccines for infectious diseases. For instance,
although some viruses exhibit a high degree of strain-to-strain vari-
ation at the protein level, highly conserved, immunogenic T cell
epitopes can be identified using computational methods; examples
can be found in preclinical studies related to tuberculosis (TB),
Human Immunodeficiency Virus (HIV), smallpox and H. pylori
published by our group9-16 and in those published by other gene-
to-vaccine researchers (Sette and Newman,17 Brusic,18 Petrov-
sky,19 Reche,20 and He,21 for example). Vaccines that include
multiple epitopes in a single delivery vehicle have been shown to
elicit epitope-specific, broad-based immune response, conferring
protection against several strains. These vaccines performed at
least equivalent to existing whole-protein vaccines, and may show
improved efficacy when compared to the whole organism or lysate
in animal challenge studies.22,23 Furthermore, epitope-based vac-
cines limit the antigenic load, diminishing the need to manufac-
ture and administer large quantities of immunogen, much of
which will be immunologically irrelevant or potentially tolero-
genic. New immunoinformatics tools also make it possible to
select potent T effector epitopes and to remove epitopes that may
drive immunopathogenic or immune modulating responses by
virtue of cross-reactivity with (human) host sequences.24-27
Only two comprehensive vaccine design toolkits have been
developed to date. Dr. Yonqun He of University of Michigan has
concatenated previously developed “public” tools with other tools
developed by his group to construct a toolkit that can be used to
select vaccine components; limited validation of this toolkit has
been published.28 In contrast, the set of tools comprised in the
iVAX toolkit was developed entirely by the team of De Groot and
Martin, with the support of the NIH (NIAID/DAIT), and these
tools are currently in use by EpiVax, its commercial clients and
academic collaborators. Use by vaccine researchers for collaborative
research programs is provided through EpiVax’ academic partner,
the Institute for Immunology and Informatics (iCubed) at the
University of Rhode Island. External collaborators are actively
using these tools for a wide range of vaccine programs that are in
progress, including research on vaccines against neglected tropical
diseases such as Chagas disease, malaria, and HIV.
Significant advancements in immunome-derived, epitope-
driven vaccines designed using the iVAX toolkit have been made
in recent years; in particular, basic research studies have demon-
strated the ability of the tools to select epitopes for Burkholderia
species,29 H. pylori30 and HCV,31-33 and validated the importance
of the presence of T cell epitopes in subunit vaccines. Recently,
the collaborating groups at EpiVax and iCubed discovered epito-
pes that activate T regulatory cells (Tregs) in viral pathogens using
Figure 1. Increasing number of immunology studies involving in silico
approaches over the last decade. Metrics were extracted from NCBI
PubMed for search terms indicated. In the case of epitope prediction,
keywords were linked together within quotations in order to return
relevant results.
Figure 2. Computational immunology word cloud. Computational
immunology Google search term results were input into the Wordle
word cloud generator (http://www.wordle.net/) that sizes terms by fre-
quency. The Google search for computational vaccinology terms was
performed in March 2015.
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the JanusMatrix tool.24,34-36 Epitope-driven vaccines designed
using the iVAX toolkit have been tested using a number of new
delivery methods that will also be reviewed below.
Computational vaccine design tools, the iVAX toolkit
Epitope mapping and design tools
iVAX is an immunoinformatics toolkit consisting of inte-
grated algorithms that facilitate the generation of epitope-based
vaccines from whole genome sequences, comprising EpiMatrix,
ClustiMer, Conservatrix, EpiAssembler, VaccineCAD, and
JanusMatrix (Fig. 3). These algorithms are described in detail in
the following sections, followed by a brief series of case studies
that illustrate their use in vaccine design.
EpiMatrix
At the heart of the iVAX toolkit is EpiMatrix, an algorithm
that models the interaction between a linear peptide and a mole-
cule of the Major Histocompatibility Complex (MHC, or HLA
in humans).37 This binding event initiates the cascade of cellular
signals that are necessary for a protective immune response.
Advances in the development of the tool and careful curation of
the training data (sets of T cell epitopes known to bind to the tar-
get HLA) have improved the accuracy of the tool over time.38
EpiMatrix parses input protein sequences into overlapping
‘frames’ of 9 amino acids, corresponding to the minimal length
of an HLA-binding peptide. As each frame overlaps the previous
one by 8 residues, all possible frames are considered. Using a
position-specific scoring matrix, each 9-mer is assigned a score
for its predicted likelihood to bind a panel of class I (A*0101,
A*0201, A*0302, A*2402, B*0702, and B*4403) and class II
(DRB1*0101, 0301, 0401, 0701, 0801, 1101, 1301, and 1501)
HLA molecules whose amino acid preferences cover the genetic
diversity of >95% of human populations worldwide.39,40 While
it may appear that this selection of alleles is limited compared to
other epitope-prediction websites, EpiMatrix exploits the obser-
vation that families of HLA alleles share specific pocket preferen-
ces,41 mitigating the problem of HLA polymorphism and
diminishing the epitope-mapping redundancy that is problematic
for other prediction tools. By tuning its predictive algorithms
based upon representative members of these families, called
“archetypes,” EpiMatrix achieves broad HLA coverage without
requiring predictions for a large number of individual haplotypes.
Furthermore, EpiMatrix allele-specific scores are normalized
to a standard scale that is based on the observed frequency of T
cell epitopes occurring in a set of random protein sequences (over
10,000 such sequences were used to develop the standard), allow-
ing predictions to be compared across multiple alleles. Standardi-
zation allows epitopes to be scored based on their deviation from
expectation, a z-score of at least 1.64 indicates that for a given
HLA allele, the 9-mer belongs to the top 5% of predicted binders
and is thus worthy of further consideration. Of course, a number
of alternative predictors of HLA binding also exist and are avail-
able online; the last head-to-head comparison between EpiMatrix
and other available epitope-mapping tools was published in 2009
[38] and new comparison is due in 2015.
However, HLA binding properties, though critical, are not
sufficient to drive significant protection against challenge. Other
factors that may not be identified by HLA binding predictors
govern whether an epitope should be included in a vaccine. The
presence of proteolytic cleavage motifs,42 probability of transport
into the appropriate pathway,43 epitope flanking residues
required for T cell recognition44,45 or cross-conservation with the
human proteome24 may all impact immunogen selection. New
tools contained in the iVAX toolkit described below address
some of these considerations.
JanusMatrix
Over the past several years, networks of cross-reactive T cell
epitopes have been discovered.46-48 At the level of an HLA-
bound peptide, certain amino acids are in contact with the HLA
Figure 3. Integration of iVAX into the epitope-driven vaccine develop-
ment pipeline. A development pathway from genome to vaccine is
shown. Pathogen-derived genetic sequences obtained from various
sources are initially built into a database in iVAX. T cell epitope vaccine
candidates are selected using epitope identiﬁcation and homology algo-
rithms according to user-deﬁned preferences for HLA coverage, patho-
gen strain coverage and T cell cross-reactivity. Vaccine construction
algorithms assemble epitope ensembles into multi-epitope sequences
containing the necessary and sufﬁcient epitope content to activate
strong T cell responses speciﬁc to the target pathogen. iVAX accelerates
epitope identiﬁcation in comparison with experimental methods using
overlapping peptide libraries, for example. In silico predictions are con-
ﬁrmed using in vitro methods and vaccines are produced and tested for
immunogenicity and efﬁcacy.
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molecule itself while others are accessible to the T-cell receptor
(TCR). If TCR-facing residues from a pathogenic epitope are
conserved among multiple HLA-binding sequences from the
human genome, the pathogenic epitope may activate T cells spe-
cific to these human proteins. This may lead to a lack of response
due to low precursor T cell frequency,49 a regulatory response
generated by natural Tregs, or a harmful autoimmune response,
all of which are unwanted effects in a vaccine. To address these
possibilities, we developed JanusMatrix to identify EpiMatrix-
predicted epitopes that may activate tolerogenic or auto-reactive
effector T cells.
JanusMatrix searches a large database of human proteins for 9-
mers with the same TCR-facing amino acids as those of the input
pathogen epitopes (Fig. 4).24,34 The HLA-facing residues of the
human 9-mer may vary as long as binding to at least one of the
same alleles as the input 9-mer is preserved. In this way, epitopes
that are potentially cross-reactive with the human host may be
located and removed from consideration for a vaccine. Pathogen
sequences can also be screened against other sequence databases
built into the tool, such as human microbiome human pathogen
databases. The role of JanusMatrix in vaccine design has been
highlighted in several recent publications, which describe the dis-
covery of putative Treg-inducing epitopes in HCV,25 HIV50 and
influenza A .34,35
By the same token, JanusMatrix may be used to identify rela-
tionships between an input peptide and published epitopes that
have been submitted to the Immune Epitope Database,3 or
indeed, any peptide or protein sequence set uploaded by the user.
This TCR-focused approach provides a novel alternative to tradi-
tional methods of cross-reactivity prediction that rely on whole
sequence alignment such as BLAST.51 In a recent analysis, we
found that epitopes deposited in IEDB that had a higher degree
of cross-reactivity with the human genome were significantly
more likely to be associated with an IL-10 or null (binding but
no immune response) and a lower IL-4 response than epitopes
that had a lower level of cross-reactivity (Fig. 5).
Conservatrix
For pathogens that exhibit significant diversity, adequate
representation at the epitope level can be challenging. Thus,
Figure 4. Immune Camouﬂage. Bacteria and viruses have evolved a
number of subterfuges to escape immune response. A recently discov-
ered strategy is to disguise T cell epitopes that may be presented by anti-
gen presenting cells as “self proteins” that are recognized by Tregs (pink
and gray) rather than T effector epitopes (blue).
Figure 5. JanusMatrix prediction of epitope cytokine proﬁles. A retro-
spective survey of epitope-speciﬁc cytokine production data docu-
mented in IEDB shows that JanusMatrix analysis of epitope humanness
differentiates between cytokine-positive and –negative data of regula-
tory and effector T cell cytokines. Peptides documented as IL-10-positive
have signiﬁcantly higher potential for human T cell cross-reactivity. Pep-
tides documented as IL-4-positive have signiﬁcantly lower potential for
human T cell cross-reactivity.
Figure 4. (B) JanusMatrix, Epitope Networks for a Regulatory and Effec-
tor T cell epitopes. T cell epitope networks were produced for a regula-
tory T cell epitope from hepatitis C virus (A) [24] and an effector T cell
epitope from inﬂuenza (B) [47], using JanusMatrix and Cytoscape. Poten-
tially cross-reactive T cell epitopes were identiﬁed by JanusMatrix, which
searches proteins in human genome (left), human microbiome (center),
and human pathogen genome (right) databases for HLA ligands with
TCR-facing residues identical to each of the query epitopes. Green dia-
monds represent source peptides; gray squares are predicted 9-mer epit-
opes derived from the source peptide; blue triangles are 9-mers that are
100% identical to the TCR face of the source epitope and that are pre-
dicted to bind to the identical HLA; and light purple circles (on the outer
rim of the array) are proteins containing the cross-reactive epitope.
www.tandfonline.com 2315Human Vaccines & Immunotherapeutics
D
ow
nl
oa
de
d 
by
 [7
2.2
15
.23
6.2
54
] a
t 1
3:3
1 0
2 S
ep
tem
be
r 2
01
5 
prior to identifying putative HLA ligands in the protein
sequence of a pathogen, the search space may be efficiently
reduced by only considering sequences that are shared among
many strains of the vaccine target. Conservatrix facilitates the
process of selecting conserved 9-mers by parsing input sequences
from multiple strains, clades, or organisms into component
strings and searching for matches.52 The output table includes
information on the frequency of each string in the dataset and
the identified conserved sequences can be used as an input
sequence for EpiMatrix analysis. This tool has been used for
defining conserved epitopes in HIV, HCV, influenza, and more
recently, Burkholderia.10,12,14,31
ClustiMer
EpiMatrix output is formatted for clear visual interpretation
of 9-mer frames predicted to bind multiple HLA alleles. When a
whole protein sequence is viewed in this way, it becomes appar-
ent that regions spanning multiple 9-mers containing high HLA
Class II binding potential are not randomly distributed through-
out, but tend to cluster. The minimal cluster, called an “EpiBar,”
is observed when a single 9-mer frame is capable of binding at
least 4 common HLA Class II alleles. To take advantage of this
clustering phenomenon and allow down-selection of these
regions for epitope-driven vaccine development (and as input
into the tools described next), we developed ClustiMer, an algo-
rithm that identifies segments of 15–30 amino acids with ele-
vated class II HLA binding promiscuity, called epitope cluster.53
Correlation with existing immunodominant and promiscuous
epitopes is very high, as was described in a previous publication
by our group.53
Immunogenicity scale
Considering potential T cell immunogenicity at the protein
level can help identify promising whole antigen vaccine candi-
dates. Immunogenic potential over the length of a protein
depends on epitope density. The greater the density, the greater
the potential to stimulate humoral and cell-mediated immune
mechanisms required for protective immunity. EpiMatrix com-
putes whole protein scores by summing top 5% binder scores
across all common HLA alleles, normalizing for a 1000-amino
acid protein length and determining the deviation from random
expectation. On a scale ranging from ¡50 to C50 or greater,
where random expectation is zero, EpiMatrix protein scores
above zero indicate the presence of more MHC ligands than
expected due to chance and denote a higher potential for immu-
nogenicity (Fig. 6). Scores below zero indicate the presence of
fewer potential MHC ligands than expected and a lower potential
for immunogenicity. Proteins scoring above C20 on this scale are
considered to have significant immunogenic potential.
Vaccine design tools
EpiAssembler
Although including epitopes and/or clusters with broad HLA
coverage and selecting peptides that are represented in multiple
strains of the target pathogen are addressed by Conservatrix and
ClustiMer, sometimes the most conserved linear sequences have
very few T cell epitopes, while the least conserved are epitope-
rich. Starting with an EpiBar 9-mer frame, EpiAssembler
searches other input sequences (from other strains of the same
pathogen, for example) for overlapping frames with the optimal
combination of HLA promiscuity and sequence conservation,
and integrates them into a chain of amino acids called an Immu-
nogenic Consensus Sequence (ICS).12 Because the construction
of an ICS is a goal-directed process, the final ICS may not be
identical to any peptide originally present in any of the input
sequences or strains; however, each overlapping 9-mer frame is
both highly conserved and putatively immunogenic. It is there-
fore possible to capture the breadth of HLA polymorphism and
the depth of pathogenic variation with a relatively small number
of ICS peptides. ICS epitopes have been used in epitope-based
vaccines by our group with significant success.22,23,54
VaccineCAD
Using the aforementioned tools, a trained user can rapidly
narrow the range of possible vaccine candidates to a collection of
epitope-rich, highly conserved, non-autologous peptides, which
may be delivered as a concatemer by linking the peptides together
in a “string-of-beads.” One potential pitfall is the emergence of
new epitopes at the junction between peptides. To overcome
Figure 6. EpiMatrix protein immunogenicity scale. EpiMatrix protein
immunogenicity scores higher than C20 are considered to be potentially
immunogenic. On the left of the scale are well-known proteins for com-
parison. Low-scoring proteins near the bottom of the scale are known to
engender little to no immunogenicity while higher scoring proteins near
the top of the scale are known immunogens.
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potential non-specific immunogenicity stimulated by these
sequences, VaccineCAD shuffles the order of the peptides until it
finds an arrangement in which junctional immunogenicity is
minimized between adjacent peptides.23 In some cases, spacers
that disrupt HLA binding (e.g. GPGPG for class II) may be
inserted if junctional epitopes remain. The end result is a chain
of peptides containing a minimum of extraneous HLA binding
potential. This construct may be reverse-translated into a nucleo-
tide sequence for DNA vaccination if desired, or for recombinant
production of a protein vaccine. Alternative formats for incorpo-
rating epitope strings into vaccines include fusions to whole anti-
gens that assemble into virus-like particles55 and biotinylated
peptide strings that self-assemble with peptide antigen carriers.56
Case Studies
The iVAX toolkit has been extensively validated in pre-clinical
studies. Here, we describe a number of studies in which some or
all of the iVAX tools played a central role in designing vaccines
with demonstrated antigenicity and/or immunogenicity.
Vaccines for T cell-mediated immune defense against
pathogens
Tularemia
Tularemia is a highly infectious disease that is caused by Fran-
cisella tularensis. No vaccine is currently approved for public use.
Class I and class II peptides from F. tularensis were predicted
from whole genome sequences using EpiMatrix, ClustiMer and
EpiAssembler, and synthesized for analysis. The peptides bound
soluble HLA in vitro and stimulated interferon gamma (IFN-g)
secretion ex vivo using peripheral blood mononuclear cells
(PBMCs) from infected patients.57 In “humanized” transgenic
mice expressing human HLA class II DRB1*0101, challenge
with F. tularensis (5£LD50) led to the death of all control mice,
while nearly 60% of vaccinated mice survived. Additionally, the
epitope-based vaccine was associated with a significant reduction
of bacterial burden in the lungs (27,352 CFUs/mg tissue in con-
trol mice vs 13,561 CFUs/mg tissue in vaccinated mice).54
Smallpox
It is well known that the vaccinia immunization protects
against variola infection that causes smallpox. In order to develop
a safer smallpox vaccine, class II T cell epitopes conserved
between the sequences of vaccinia and variola major were
predicted by EpiMatrix, selected using Conservatrix and
concatenated using EpiAssembler and VaccineCAD.58 The epi-
tope-based “VennVax” concatemer was constructed, and a plas-
mid encoding the epitope string was delivered in combination
with peptides in liposomes in a DNA-prime/peptide-boost vacci-
nation of HLA-DR3 transgenic mice. All immunized mice
(100%) survived challenge with 10X LD50 of vaccinia WR, as
compared to 19% of the control mice. Robust T cell responses
were detected pre-challenge via IFNg ELISpot performed on
splenic leukocytes, but no antibodies were found in the serum,
suggesting that the protection was completely driven by T cells.59
This case study provides evidence that complete protection
against a viral challenge may be achieved using T cell epitopes
alone.
H.pylori
Infection by H. pylori is the most common cause of gastric
cancer, and recent antibiotic resistance has renewed interest in
developing a vaccine. To cover genetically diverse H. pylori
strains, 7 publicly available genomes were computationally
screened to identify genes that encode proteins with promising
antigenic properties. Among conserved 9-mer sequences derived
from the core genome and identified with Conservatrix, potential
class II HLA binders were predicted by EpiMatrix for a panel of
8 “supertype” alleles. EpiAssembler was used to a maximize
immunogenicity and conservation of 9-mers by constructing ICS
of 20–25 amino acids in length. The multistep computational
selection process greatly narrowed down the H. pylori antigenic T
cell epitope sequences from 1,241,153 9-mers with binding
potential to a total of 1,805 ICS encoded by 676 sequences com-
mon to all 7 genomes. The top 100 ICS (»6%), by EpiMatrix
Cluster score were selected for peptide synthesis. Overall, 76% of
synthesized peptides bound strongly to a panel of 6 classical
HLA-DR class II alleles. Human T cell responses to these 90 pep-
tides were generally increased in actively H. pylori-infected com-
pared with H. pylori-na€ıve subjects (by IFNg ELISpot and
cytokine ELISA).29 This program has not yet progressed to in
vivo studies, but a previous therapeutic vaccine containing a
concatenated string of H. pylori epitopes, predicted and delivered
in the same manner as described for the VennVax vaccine above,
was shown to clear infection.23
Burkholderia
Burkholderia pseudomallei (BPM) and Burkholderia mallei
(BM) are Category B pathogens. Burkholderia cepaciae (BC)
causes chronic lung infections in cystic fibrosis patients. No
licensed vaccines are available for these pathogens. We are devel-
oping an epitope-driven multi-pathogen vaccine against these 3
Burkholderia species.
The iVAX toolkit was used to develop ICS containing class II
T cell epitopes that were conserved in at least 2 Burkholderia spe-
cies.12 As epitope selection for this project occurred prior to the
development of the JanusMatrix tool, BLAST was used to con-
firm that none of these ICS clusters were significantly homolo-
gous to the human genome. All the ICS bound to at least 2 HLA
class II alleles for which they were predicted. Significant human
IFN-g response was induced using the Wullner et al. protocol
with modification60 in at least one donor by all (100%) 44 pepti-
des tested and in at least 3 donors by 35 peptides.
Immunogenicity of the ICS was evaluated in BALB/c and
HLA-DR3 transgenic mice by peptide and DNA-prime/peptide-
boost immunization. Overall, 29% and 11% of the ICS peptides
elicited significant IFN-g responses in splenocytes from BALB/c
and DR3 transgenic mice, respectively, as measured by ELISpot
assay. Future studies will be carried out in alternative models as
this vaccine progresses in the pre-clinical pathway.
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Hepatitis C Virus (HCV)
HCV is an etiologic agent of chronic liver disease. Although
new therapies have shown tremendous response rates, they
remain expensive, and vector-mediated vaccination with multi-
epitope expressing DNA constructs alone or in combination with
chemotherapy offers an additional treatment approach. HLA-A2
epitopes and HLA-DR ICS were designed using the iVAX toolkit
from HCV genotypes 1a and 1b. In HLA binding assays, 90%
and 84% of binding predictions were met for HLA-A2
epitopes and HLA-DR ICS, respectively. All peptides induced
IFN-g responses ex vivo in whole PBMC cultures and in
cultures of na€ıve human CD4C T lymphocytes co-cultured with
CD14C monocyte-derived dendritic cells (DC) pulsed with ICS.
These results were confirmed in a HLA-A2/DR1 transgenic
murine model vaccinated with pulsed DCs, in which peptide-
specific cytokine production was induced to 33/38 (87%) of the
vaccine-encoded HLA class I- and class II restricted T cell
epitopes.31
In addition to confirming the antigenicity of the epitopes, we
evaluated whether several epitopes that were highly conserved
with the human genome could induce responses in PBMC cul-
tures obtained from chronically infected patients and spontaneous
clearers. A highly conserved viral epitope (HCV_G1_p7_794)
from HCV non-structural protein p7 induced a marked increase
in CD3CCD4CFoxP3C T cells in PBMC donated by chronically
infected patients, but not from uninfected individuals or patients
who spontaneously resolved infection.25
These CD3CCD4CFoxP3C T cells exhibited Treg activity,
suppressing the mitogenic response of PBMCs obtained from the
same infected patients. HCV_G1_p7_794 alone did not stimu-
late Treg cell proliferation, but promoted conversion of conven-
tional CD3CCD4CFoxP3¡ T effector cells to an induced
Treg cell population. JanusMatrix analysis indicated that
HCV_G1_p7_794 contained sequences whose TCR-facing resi-
dues are shared with epitopes associated with hundreds of human
proteins, strengthening the evidence that the presence of this
epitope should be avoided in HCV vaccine design (Fig. 3b).
Accelerated response to bioterror threats
In the case of an outbreak or bioterror attack, response
time is a crucial factor in effectively containing a potential
epidemic. In order to test the epidemic-preparedness of the
iVAX technology for developing ‘vaccines ‘on demand’, the
“VaxCelerate” consortium was developed.61 In a ‘live fire’
Lassa virus vaccine program, a vaccine composed of a high
quality set of 12 putative HLA class I-restricted epitopes and
6 putative HLA class II-restricted T cell epitope clusters was
constructed in under 30 days. Epitopes were optimized to
contain minimal human cross-reactive epitope content, maxi-
mal validation in the literature and sufficient epitope content
to observe immune responses in HLA-DR3 transgenic mice.
A vaccine was formulated with 6 biotinylated peptides, each
composed of a string of 2 class I epitopes and one class II
epitope that self-assembled with MTB-HSP70-avidin. Prelim-
inary immunization results demonstrated increased CD4C
IFN-gC T cell frequencies in immunized mice.56
Other applications of the iVAX toolkit
Predicting the need for a new vaccine, Pandemic H1N1
H1N1, a novel swine-origin influenza virus (S-OIV)
emerged in Mexico and the Western United States in March
2009. In advance of the development of a new H1N1 vac-
cine, our team used EpiMatrix and Conservatrix to identify
T helper and cytotoxic T lymphocyte (CTL) epitopes con-
served between S-OIV and 2008–9 CIV in the hemagglutinin
(HA) antigen.14 Based on the analysis, we predicted that
there would be moderate to high cross-reactivity in the HA
epitopes between the pandemic virus and the 2008–9 sea-
sonal flu vaccine, and that some protection against morbidity
may be conferred by prior influenza exposure or seasonal
influenza vaccination. The predicted cross-reactivity of these
epitopes was later confirmed using blood samples from
S-OIV-exposed humans and H1N1-na€ıve, CIV-immunized
subjects.13
Prior to 2013, H7N9 influenza virus was known to infect poul-
try only, giving humans little to no immunity against it.62 The
ongoing circulation of H7N9 in poultry and potential for the virus
to be efficiently transmitted from human to human poses a serious
threat to public health, raising the development of an effective pro-
phylactic vaccine to a high priority. Unfortunately, attempts at
designing an effective vaccine have been largely unsuccessful. For
example, whole-inactivated H7N9 vaccines failed to protect ferrets
from the infection, and subunit vaccines developed using H7 HA
were poorly immunogenic in humans.63-66
Predicting vaccine efficacy, H7N9
H7N9 provides an opportunity to showcase 2 iVAX tools. In
addition to the low number of CD4C T cell epitopes predicted
by EpiMatrix in H7 HA (as shown in Fig. 7, on the EpiMatrix
immunogenicity scale), JanusMatrix predicted that several exist-
ing epitopes were highly cross-conserved with the human genome
Figure 7. Potential immunogenicity of avian H7 and seasonal inﬂuenza
HA. Avian H7 HA proteins possess low immunogenic potential based on
EpiMatrix-predicted CD4C T cell epitope content. In contrast recent circu-
lating seasonal HAs bear higher potential and fall within the positive
range of the scale. Lower epitope content in H7N9 HA may explain, in
part, lower H7N9 immunogenicity observed in infection and vaccination.
Re-published from Hum Vaccin Immunother. 2014;10(2),256-62 with
permission.
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on the TCR side, suggesting that the H7N9 may ‘camouflage’
itself to appear human [34]. Consistent with this prediction,
immunoreactivity screening results using na€ıve human PBMCs
revealed that the degree of cross-conservation of predicted epito-
pes with the human genome was inversely correlated with their
immunogenicity.67 Immunophenotyping data demonstrate a
strong link between these ‘human-like’ epitopes and Treg expan-
sion.35 Overall, our observations provide a possible alternative
explanation why whole inactivated H7 HA vaccines were poorly
immunogenic.
Conclusion
The lack of clinical efficacy of some previous epitope-driven
vaccines against microbial pathogens may have been due to their
(1) limited number of epitopes, (2) limited sequence conserva-
tion with clinical strains, (3) limited HLA population coverage,
and/or (4) suboptimal delivery. Recent discoveries add to this
list, (4) epitopes that trigger regulatory T cell responses due to
cross-conservation with regulatory T cell epitopes present in the
human genome appear to be one means by which human patho-
gens ‘camouflage’ immune response. Re-designing immunogens
to remove these epitopes may improve both humoral and cellular
immune responses to vaccines.50
The iVAX toolkit addresses each of these issues, enabling the
development of computationally designed, epitope-driven vac-
cines for bio-warfare agents, highly variable pathogens and
chronic infectious diseases. The number of epitopes to be
included is not a significant obstacle, evidence from animal stud-
ies suggests that the number of epitopes required for full protec-
tion is a small and definable subset (less than 50);68,69 thus,
achieving a payload of 50–100 epitopes that provide broad cover-
age of human genetic backgrounds may be sufficient to provide
protection. Improving payload quality by choosing epitopes that
demonstrate antigenicity in human PBMCs as well as protection
in established murine models of disease is now possible. Further-
more, the combination of promiscuous class II epitopes and class
I supertype epitopes can provide nearly 100% coverage of human
populations. Optimization of payload, delivery, formulation,
and adjuvanting can accelerate these vaccines to the clinic.
The use of immunoinformatics tools is not limited to
vaccines for infectious diseases. For example, T cell-driven
vaccines are becoming an adjunct immunotherapy to treat
cancer, more than 250 T-cell driven vaccines are in clinical
trials.70,71 Computational vaccinology should accelerate the
identification of immunogenic tumor antigens and improve
safety of these new treatments. In the near future, we expect
computationally engineered vaccines incorporating recent
advances in epitope discovery, vaccine design and delivery
and adjuvanting to provide effective protection against infec-
tious diseases as well.
In conclusion, the investigators using computational vaccinol-
ogy tools have advanced many of the immunoinformatics-
designed vaccines described above to the point of formulation
and delivery studies over the past 5 years. Sufficient proof of
principle has been gathered to suggest that the iVAX vaccine
toolkit can be used to design effective vaccines. The toolkit is cur-
rently being used in studies that propose to accelerate production
of vaccines in response to a bioterror event or to outbreaks of dis-
ease that can rapidly spread, such as Ebola in West Africa. The
need for new vaccines for protecting against bioterror pathogens
and emerging infectious disease is great, and we would argue for
the reasons cited above, that the time to integrate computational
vaccinology into all existing vaccine pipelines and to advance
these vaccines to the clinic is now.
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